Market Access Views & Analysis

Views & Analysis

A novel approach to detecting Alzheimer’s early

The grey matter in the brain may hold vital clues for early, accurate detection in Alzheimer’s, and potentially also help pharma to find new drug treatments.

Views & Analysis

Improving access and reimbursement for specialty therapies

As specialty therapies move toward long-term maintenance use and as treatment times grow longer, government and commercial payers are scrutinising the economic value of new treatments more

Views & Analysis

Market access in the time of COVID-19

COVID-19 has left no part of life untouched, including health technology assessment (HTA) and other payer agency activities, and it will likely have a lasting impact on market access.

Views & Analysis

Breaking policy and perceptual barriers: Biosimilars

Experts from Research Partnership analyse the company’s Therapy Watch data to identify how market access policy has impacted the adoption of biosimilars.

Views & Analysis

Teva’s Kim Innes on shaping the post-COVID future with the N...

Like all UK pharma GMs working during the COVID-19 pandemic, Teva’s Kim Innes has found herself leading her company through an unprecedented crisis in one of the worst-hit countries in the

Views & Analysis